Analyst firms · Morgan Stanley · PTCT
Morgan Stanley PTCT price target and rating history
PTC Therapeutics Inc. (PTCT) · Health Care
Morgan Stanley rates PTC Therapeutics Inc. (PTCT) Overweight with a $67 price target, as of its latest action on Dec 13, 2024. It has published 3 rating actions on PTCT since September 2022, including 1 upgrade and 1 downgrade. Across 8 firms with a PTCT price target in the last 12 months, the median target is $94.50.
- Current rating
- Overweight
- Price target
- $67
- Median target, all firms
- $94.50
- Actions on PTCT
- 3
Morgan Stanley price target on PTCT
Every Morgan Stanley rating on PTCT
- Dec 13, 2024
- Dec 19, 2023
- Sep 9, 2022
How other firms rate PTCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Hold | $62 | Oct 16, 2026 |
| Leerink Partners | Outperform | $98 | Sep 14, 2026 |
| Citigroup | Buy | $108 | Jun 9, 2026 |
| Jefferies | Buy | $85 | May 27, 2026 |
| TD Cowen | Buy | $90 | May 8, 2026 |
| Raymond James | Outperform | $108 | Apr 10, 2026 |
| Barclays | Overweight | $119 | Jan 28, 2026 |
| RBC Capital Markets | Sector Perform | $91 | Dec 1, 2025 |
Questions about Morgan Stanley and PTCT
- What is Morgan Stanley's price target for PTCT?
- Morgan Stanley's latest stated price target for PTC Therapeutics Inc. (PTCT) is $67, from its action on Dec 13, 2024.
- What is Morgan Stanley's rating on PTCT?
- Morgan Stanley rates PTCT Overweight, a bullish rating, as of Dec 13, 2024.
- When did Morgan Stanley last change its view on PTCT?
- On Dec 13, 2024, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $45 to $67.
- How does Morgan Stanley's PTCT target compare with other analysts?
- Across 8 firms with a PTCT price target in the last 12 months, the median target is $94.50.
More PTCT rating histories
All Morgan Stanley ratingsPTCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.